Stakeholder Input
Authors
- Pages
- 209
- Published in
- Canada
CADTH Reimbursement Review - Evinacumab (Evkeeza) - Sponsor: Ultragenyx Pharmaceutical Inc. Therapeutic area: Homozygous familial hypercholesterolemia
18 Apr 2024
Accessing this content requires a membership
If your institution is a member, please log into Canada Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.
Add to list
Citation
Health, C., 2024. CADTH Reimbursement Review - Evinacumab (Evkeeza) - Sponsor: Ultragenyx Pharmaceutical Inc. Therapeutic area: Homozygous familial hypercholesterolemia, Canadian Agency for Drugs and Technologies in Health.
Canada.
Retrieved from https://coilink.org/20.500.12592/bg79k4x on 08 Sep 2024. COI: 20.500.12592/bg79k4x.
Full-page Screenshot
